Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul;23(3):229-230.
doi: 10.5217/ir.2025.00114. Epub 2025 Jul 29.

Upadacitinib after tofacitinib in ulcerative colitis

Hyeon Jin Cho  1 , Eun Soo Kim  1
Affiliations
Editorial

Upadacitinib after tofacitinib in ulcerative colitis

Hyeon Jin Cho et al. Intest Res. 2025 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Kim ES is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Comment on

References

    1. Singh S, Loftus EV, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307–1343. - PMC - PubMed
    1. Gilmore R, Fernandes R, Hartley I, et al. Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intest Res. 2025;23:347–357. - PMC - PubMed
    1. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–2128. - PubMed
    1. Miyoshi J, Morikubo H, Yonezawa H, Mori H, Hisamatsu T. First aid with color atlas for the use of intestinal ultrasound for inflammatory bowel disease in daily clinical practice. Intest Res. 2023;21:177–188. - PMC - PubMed
    1. Tamura A, Shimizu H, Fujii T, et al. Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan. Intest Res. 2025 Mar 20; doi: 10.5217/ir.2024.00187. [Epub]. - DOI - PubMed

LinkOut - more resources